These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 37051060)

  • 1. The effects of safinamide according to gender in Chinese parkinsonian patients.
    Pellecchia MT; Picillo M; Russillo MC; Andreozzi V; Oliveros C; Cattaneo C
    Sci Rep; 2023 Nov; 13(1):20632. PubMed ID: 37996493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of Safinamide in Chinese and Non-Chinese Patients with Parkinson's Disease.
    Cattaneo C; Kulisevsky J
    Adv Ther; 2024 Feb; 41(2):638-648. PubMed ID: 38070039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of safinamide on morning-off phenomenon in elderly patients with Parkinson's disease].
    Takizawa S; Kohara S; Sato F; Takahashi W
    Nihon Ronen Igakkai Zasshi; 2023; 60(4):390-399. PubMed ID: 38171756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SYNAPSES. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: post-hoc analysis of the Spanish study population.
    Kulisevsky J; Esquivel A; Freire-Álvarez E; Gómez-Esteban JC; Legarda-Ramírez I; Avilés A; Mata-Álvarez-Santullano M
    Rev Neurol; 2023 Oct; 77(s02):1-12. PubMed ID: 37752685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Safinamide on Patient-Reported Outcomes in Parkinson's Disease.
    Espinoza-Vinces C; Villino-Rodríguez R; Atorrasagasti-Villar A; Martí-Andrés G; Luquin MR
    Patient Relat Outcome Meas; 2023; 14():285-295. PubMed ID: 37840836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spanish expert consensus on the use of safinamide in Parkinson's disease.
    Valldeoriola F; Grandas F; Arbelo JM; Blázquez Estrada M; Calopa Garriga M; Campos-Arillo VM; Garcia Ruiz PJ; Gómez Esteban JC; Leiva Santana C; Martínez Castrillo JC; Mir P; Salvador Aliaga A; Vivancos Matellano F; Yáñez Baña RM
    Neurologia (Engl Ed); 2018 Jul; ():. PubMed ID: 30072274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice.
    Pagonabarraga J; Arbelo JM; Grandas F; Luquin MR; Martínez Martín P; Rodríguez-Oroz MC; Valldeoriola F; Kulisevsky J
    Brain Sci; 2020 Mar; 10(3):. PubMed ID: 32197462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safinamide for pain management in patients with Parkinson's disease.
    Abilashimova D; Aubakirova M; Abdildin Y; Viderman D
    Rev Neurol (Paris); 2023 Dec; ():. PubMed ID: 38103994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice.
    Pérez-Torre P; López-Sendón JL; Mañanes Barral V; Parees I; Fanjul-Arbós S; Monreal E; Alonso-Canovas A; Martínez Castrillo JC
    Neurologia (Engl Ed); 2021 Sep; ():. PubMed ID: 34518027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real world data of a German Parkinson's disease population: effectiveness and safety of safinamide in routine clinical practice.
    Jost WH; Gluth I; Lück JC; Lopes OIFDC;
    Curr Med Res Opin; 2023 Dec; 39(12):1621-1628. PubMed ID: 37421634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of safinamide on dysphagia in Parkinson's disease.
    Hirano M; Samukawa M; Isono C; Nagai Y
    PLoS One; 2023; 18(5):e0286066. PubMed ID: 37228084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A
    Bhidayasiri R; Koebis M; Kamei T; Ishida T; Suzuki I; Cho JW; Wu SL
    Front Neurol; 2023; 14():1147008. PubMed ID: 37051060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safinamide as an Adjunct to Levodopa in Asian and Caucasian Patients With Parkinson's Disease and Motor Fluctuations: A Post Hoc Analysis of the SETTLE Study.
    Bhidayasiri R; Ishida T; Kamei T; Husni RE; Suzuki I; Wu SL; Cho JW
    J Mov Disord; 2023 May; 16(2):180-190. PubMed ID: 37096301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
    Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
    CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence.
    Bette S; Shpiner DS; Singer C; Moore H
    Ther Clin Risk Manag; 2018; 14():1737-1745. PubMed ID: 30271159
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.